Abstract
Drug interactions with immunosuppressive drugs are a mayor problem of protease inhibitor based antiviral triple therapy of Hepatitis C virus reinfection after liver transplantation. In this retrospective cohort study we analyzed biomarkers of immunosuppressive effects of cyclosporine A (CsA) by quantifying nuclear factor of activated T cells (NFAT)-regulated gene expression during telaprevir therapy in liver transplant patients. Further more, dose adjustment and blood concentrations of CsA as well as the clinical course were analyzed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
